biostudies-literatureUnknown6(24)Izquierdo CPImmune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than tBlood advances6219-6227https://www.ebi.ac.uk/biostudies/studies/S-EPMC9792393biostudies-literatureReal-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.PMC9792393Garcia-Garcia IAvila Idrovo LFJimenez GMIzquierdo CPTallon IVarea SMoreno Beltran MEMingot-Castellano MEJimenez MMAtucha JASalinas Rde la Rubia JSole MDel Rio-Garma JHernandez LMartin PValcarcel DCampuzano VPerez-Montana AHernandez Castellet JCPaciello MLFernandez MZalba SGarcia-Arroba Peinado JGarcia-Candel FCid JEstevez JVVara MGala JMFreiria CLopez Lorenzo JLLavilla ECruz NZarzoso MFArias EGGarcia-Munoz NGomez-Segui IFuentes AEKGoterris RMoreno Macias JRfalseReal-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than t2022-01-01T00:00:00Z2022 Dec2025-04-04T12:10:10.878Z2025-04-04T12:10:10.878ZS-EPMC97923933593069410.1182/bloodadvances.2022008028